Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Apr 18;2005(2):CD003083.
doi: 10.1002/14651858.CD003083.pub2.

Benperidol for schizophrenia

S Leucht  1 , B Hartung
Affiliations
Review

Benperidol for schizophrenia

S Leucht et al. Cochrane Database Syst Rev. .

Abstract

Background: Benperidol is a relatively old antipsychotic drug that has been marketed since 1966. It has been used in Germany for 30 years, but is also available in Belgium, Greece, Italy, the Netherlands and the UK. Benperidol is a butyrophenone antipsychotic, with the highest neuroleptic potency in terms of D2 receptor blockade. Those taking it are therefore reputed to be at high risk of extrapyramidal side effects, but benperidol's unusual profile may render it valuable to subgroups of people with schizophrenia.

Objectives: To examine the clinical effects and safety of benperidol for those with schizophrenia and schizophrenia-like psychoses.

Search strategy: We searched the Cochrane Schizophrenia Group's register (November 2004) for this update.

Selection criteria: We included all randomised controlled trials that compared benperidol with other treatments for people with schizophrenia, or schizophrenia-like psychoses.

Data collection and analysis: We reliably selected studies, quality rated them and extracted data. We independently extracted data but excluded data if loss to follow up was greater than 50%. For dichotomous data, we estimated relative risks (RR), with the 95% confidence intervals (CI). Where possible, we calculated the number needed to treat/harm statistic (NNT/H) and used intention-to-treat analysis.

Main results: The update yielded no further studies for inclusion in the review. We identified only one unpublished poorly randomised controlled trial (N=40, duration 30 days, comparison perphenazine). Although benperidol was inferior to perphenazine (1 RCT, N=40, global state no better or worse RR 8.0 CI 2.1 to 30, NNH 1.4 CI 1 to 2) poor reporting suggests that an overestimate of effect is likely. It was not possible to report other outcomes.

Authors' conclusions: Currently, there are insufficient data from randomised trials to assess the clinical effects of benperidol. This compound merits further research interest.

PubMed Disclaimer

Conflict of interest statement

Christian Schwarz ‐ none known. Benno Hartung ‐ none known. Stefan Leucht ‐ received speaker/consultancy/advisory board honoraria from SanofiAventis, BMS, EliLilly, Glaxo SmithKline, Janssen/Johnson and Johnson, Lundbeck and Pfizer. He received financial support for research projects from SanofiAventis and EliLilly.

Figures

1
1
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
1.1
1.1. Analysis
Comparison 1 BENPERIDOL versus OTHER ANTIPSYCHOTICS, Outcome 1 Global state: No better or deterioration.
1.2
1.2. Analysis
Comparison 1 BENPERIDOL versus OTHER ANTIPSYCHOTICS, Outcome 2 Leaving the study early: Any reason.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

Eckmann 1984 {published data only}
    1. Eckmann F, Weber J. A comparison between perphenazine and benperidol. A controlled double blind study [Vergleich zwischen Perphenazin und Benperidol. Eine kontrollierte Doppelblind‐Studie]. Unpublished manuscript ‐ available from Cochrane Schizophrenia Group 1984.

References to studies excluded from this review

Bobon 1963 {published data only}
    1. Bobon J, Collard J, Lecoq R. Benperidol and promazine: a double‐blind comparative study in senile dementia [Benperidol et promazine: une etude comparative "double‐blind" en geriatrie mentale]. Acta Neurologica Psychiatrica Belgica 1963;63(10):839‐43. - PubMed
Collard 1964 {published data only}
    1. Collard J, Lecoq R. Benperidol and placebo: a double blind study of the treatment of neurosis in ambulatory patients [Benperidol et placebo: une etude "double blind" chez les nevroses en traitement ambulatoire]. Acta Neurologica Psychiatrica Belgica 1964;64(4):353‐5. - PubMed
Digo 1967 {published data only}
    1. Digo R, Karavokyros D, Mlynarski JC. Use of a new butyrophenone in psychiatric service. Outline of a differential study. Encephale 1967;56(1):75‐91. - PubMed
Flügel 1967 {published data only}
    1. Flügel K, Pfeiffer W. A clinical trial of benperidol [Klinische Erfahrungen mit dem Butyrophenon Benperidol]. Arzneimittelforschung 1967;17(4):483‐5. - PubMed
Haase 1964 {published data only}
    1. Haase H‐J, Mattke D, Schönbeck M. Clinical neuroleptic examination: an example of butyrephenone benperidol and spiroperidol [Klinisch‐neuroleptische Prüfungen am Beispiel der Butyrophenonderivate Benzperidol und Spiroperidol]. Psychopharmacologia 1964;6(6):435‐52. - PubMed
Muijen 1992 {published data only}
    1. Muijen M, Marks I, Connolly J, Audini B. Home based care and standard hospital care for patients with severe mental illness: a randomised controlled trial. BMJ 1992;304:749‐54. - PMC - PubMed
Nedopil 1981 {published data only}
    1. Nedopil N, Rüther E. Initial improvement as predictor of outcome of neuroleptic therapy. Pharmacopsychiatry 1981;14(6):205‐7. - PubMed
Nedopil 1985 {published data only}
    1. Nedopil N, Eben E, Klein H, Krüger R, Rüther E, Schmauss M. High‐dosage neuroleptic therapy for acute schizophrenic patients ‐ two double‐blind studies with benperidol. Pharmacopsychiatry 1985;18(1):63‐6. - PubMed
Seiler 1994 {published data only}
    1. Seiler W, Wetzel H, Hillert A, Schollnhammer G, Benkert O, Hiemke C. Plasma levels of benperidol, prolactin, and homovanillic acid after intravenous versus two different kinds of oral application of the neuroleptic in schizophrenic patients. Experimental and Clinical Endocrinology 1994;102(4):326‐33. - PubMed
    1. Seiler W, Wetzel H, Hillert A, Schollnhammer G, Langer M, Barlage U, Hiemke C. Pharmakokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application. Psychopharmacology 1994;116(4):457‐63. - PubMed
Sieberns 1986 {published data only}
    1. Sieberns S. Acute treatment of schizophrenic psychoses with benperidol [Akut‐Behandlung schizophrener Psychosen mit Benperidol]. Krankenhausarzt 1986;59(12):925‐30.

Additional references

Ahmed 1999
    1. Ahmed I, Soares K, Seifas R, Adams CE. Randomised controlled trials in Archives of General Psychiatry (1959‐1995): a prevalence study. Archives of General Psychiatry 1998;55:754‐5. - PubMed
Altman 1996
    1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. - PMC - PubMed
Begg 1996
    1. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz K, Simel D, Stroup D. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276(8):637‐9. - PubMed
Bland 1997
    1. Bland JM, Kerry SM. Trials randomised in clusters. BMJ 1997;315:600. - PMC - PubMed
Boissel 1999
    1. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405‐11. - PubMed
Carpenter 1994
    1. Carpenter WT, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681‐90. - PubMed
Deeks 2000
    1. Deeks J. Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐29th; Cape Town, South Africa. Cape Town: Cochrane Collaboration, 2000.
Der‐Simonian 1986
    1. Der‐Simonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88. - PubMed
Divine 1992
    1. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623‐9. - PubMed
Donner 2002
    1. Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971‐80. - PubMed
Egger 1997
    1. Egger M, Smith GD, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315:629‐34. - PMC - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31:140‐9. - PubMed
Fachinformation 1999
    1. Bayer Vital Gmbh. Glianimon (R). Fachinformation 1999:1‐4.
Fluegel 1967
    1. Fluegel KA, Pfeiffer WM. A clinical trial of benperidol [Klinische Erfahrungen mit dem Butyrophenon Benperidol]. Arzneimittelforschung 1967;17(4):483‐5. - PubMed
Gulliford 1999
    1. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876‐83. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2008
    1. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions version 5.0.1 (updated September 2008). The Cochrane Collaboration. Available from www.cochrane‐handbook.org. John Wiley & Sons, 2008.
Jüni 2001
    1. Jüni P, Altman D, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323:42‐6. - PMC - PubMed
Kay 1986
    1. Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. North Tonawanda (NY): Multi‐Health Systems, 1986.
Langer 1983
    1. Langer G, Heimann H. Psychopharmaka, grundlagen und therapie. Berlin, Heidelberg, New York: Springer Verlag, 1983.
Leucht 2005a
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231‐8. - PubMed
Leucht 2005b
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366‐71. - PubMed
Marshall 2000
    1. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52. - PubMed
Marvaha 2004
    1. Marwaha S, Johnson S. Schizophrenia and employment ? a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337‐49. - PubMed
Milton 2001
    1. Milton J, Logan S, Gilbert R, Patel S. How well are recent randomised controlled trials reported?. Proceedings of the 9th International Cochrane Colloquium, 2001 Oct 9‐13th, Palais des Congrès, Lyon, France. 2001.
Nedopil 1979
    1. Nedopil N, Ruether E, Zander K. Comparison of a high and a medium dosage of benperidol in antipsychotic treatment [Vergleich einer hohen und einer mittleren dosierung von benperidol bei der antipsychotischen therapie]. Ärztliches Gespräch 1979;18(30):7‐19.
Overall 1962
    1. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799‐812.
Tsuang 1978
    1. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153‐55. - PubMed
Ukoumunne 1999
    1. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1‐75. - PubMed
Xia 2007
    1. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, Pinfold V, Takriti Y. The Leeds Outcomes Stakeholders Survey (LOSS) Study. Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23‐27; Sao Paulo,. 2007.

References to other published versions of this review

Leucht 2005
    1. Leucht S, Hartung B. Benperidol for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003083.pub2] - DOI - PMC - PubMed

MeSH terms